AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02407184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Newborn exposure to mother vaginal microbiota
Description: Babies are swabbed just after delivery with gauze containing their mother's vaginal microbiota.
Study NCT03107650 — intervention group
Intervention type: PROCEDURE
Intervention: Transanal total mesorectal excision of rectal cancer
Description: To perform a total mesorectal excision through a transanal approach
Study NCT00606073 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Universal IVF Medium + ISM1 Medium
Description: Sibling oocytes will be equally divided and incubated separately in different 4-well culture dishes containing either IVF medium or ISM1 Medium and while ICSI will be returned to the same culture dish following injection. Fertilization assessment will be performed approximately after 15-20 hours for standard IVF and 12-18 hours post ICSI performance. After assessment, fertilized oocytes from different culture media will be transferred separately into fresh culture dishes containing ISM1 medium only. The zygotes will be incubated until embryo transfer on day 2 or 3. Embryo quality will be assessed according to the morphology of blastomeres as well as it's developmental stage.
Study NCT03545776 — intervention group
Intervention type: OTHER
Intervention: Critical Care EEG Course
Description: Medical and nursing staff will be given a 10-points EEG face-to-face initial training course followed by an online teaching and educational quizzes at day-1, day-15 and day-30 after initial training. A final evaluation will be performed at day-90 after beginning of the training course.~10-points EEG educational objectives : physiological rhythms, reactivity, symmetry, effects of sedation, burst suppression, paroxysmal activities, periodic / pseudoperiodic activities, rhythmic activities, artifacts, null EEG
Study NCT01290601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: Tafenoquine: 2 capsules (200mg base/capsule for a total of 400mg base) and 4 chloroquine placebo capsules for 2 days, followed by 2 tafenoquine capsules and 2 chloroquine placebo capsules for 1 day, followed by 1 primaquine placebo capsule/day for 14 days.
Study NCT01290601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine + Primaquine
Description: Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 2 day, followed by chloroquine (500 mg chloroquine phosphate) and tafenoquine placebo x 1day, followed by primaquine, 15 mg/day for 14 days.
Study NCT01290601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafenoquine
Description: Tafenoquine (600 mg base) and chloroquine placebo x 1d, chloroquine placebo x 2 days, followed by primaquine placebo for 14 days.
Study NCT01290601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine + Primaquine
Description: Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 1 day, followed by chloroquine (1000 mg chloroquine phosphate) x 1 day, followed by chloroquine (500 mg chloroquine phosphate) x 1day, followed by primaquine, 15 mg/day for 14 days.
Study NCT01722149 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Adoptive Transfer of re-directed T cells
Description: Adoptive Transfer of 10e6 re-directed T cells in the pleural effusion
Study NCT00704002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: antegrade intramedullary splinting
Description: antegrade intramedullary splinting with 2 to 3 small K-wires
Study NCT00704002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conservative treatment
Description: conservative treatment with 2-finger splint for one week
Study NCT01349023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy density (ED), Energy content
Description: Standard or reduced energy content and energy density of pre-portioned entrees
Study NCT02690558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab, gemcitabine and cisplatin
Description: neoadjuvant administration of pembrolizumab with gemcitabine and cisplatin prior to cystectomy
Study NCT02729103 — intervention group
Intervention type: DRUG
Intervention: Xofigo (Radium 223 dichloride,BAY88-8223)
Description: Retrospective claims analysis. Descriptive analyses of treatment patterns.
Study NCT02977117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysate magnesium (1.0 mmol/L)
Description: Dialysate magnesium will be increased from 0.5 mmol/L to 1.0 mmol/L for 4 weeks after which subjects will return to dialysate magnesium 0.5 mmol/L for 2 weeks observation.
Study NCT02977117 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dialysate magnesium (0.5 mmol/L)
Description: Dialysate magnesium will be maintained at 0.5 mmol/L for the duration of the trial.
Study NCT01765179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate
Description: Initial dose 200 mg T, BID; dose titration Days 42 and/or 84 based on serum T levels obtained 3-5 hours post AM dose on Days 30 and 72. Dosages increased or decreased in 50 mg increments.
Study NCT02608281 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CONTRAST ENHANCED DUAL ENERGY (CEDEM)
Description: The CEDEM application requires the intravenous injection of iodide contrast agents. For each projection view (CC, MLO) a low and a high energy x-ray image will be acquired after Iodine based contrast medium administration. Patient will undergo CE MRI procedure.
Study NCT03838107 — intervention group
Intervention type: BEHAVIORAL
Intervention: observation and measure of trajectory of recovery in CRPS
Description: Child participants enrolled in this study will undergo three sessions, which will include psychosocial measures, brain imaging, and quantitative sensory testing. Parent participants will also complete three sessions, which only include psychosocial measures.
Study NCT00419783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bilastine
Description: 20 mg tablets.
Study NCT00419783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: 100 mg (5 tablets of 20 mg)
Study NCT00419783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilastine & Ketoconazole
Description: 1 capsule containing bilastine 20 mg tablet + ketoconazole 400 mg tablet
Study NCT00419783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 1 capsule containing moxifloxacin 400 mg tablet
Study NCT00419783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study NCT01272947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Description: Topical gel 1%- 4 times daily
Study NCT01272947 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical gel - 4 times daily
Study NCT00279630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthoses and Exercise
Description: orthrose and exercise - daily
Study NCT04498065 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological data
Description: Biological data
Study NCT04498065 — intervention group
Intervention type: OTHER
Intervention: Clinical data
Description: Clinical data
Study NCT01789125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Study NCT01789125 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Termination and Anxiety Reduction Treatment
Description: Integrated smoking cessation and anxiety reduction treatment
Study NCT01789125 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education-Supportive Psychotherapy
Study NCT00287339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40mg capsule BID for 12 weeks
Study NCT00287339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule BID for 12 weeks
Study NCT00564018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Description: Dosage adjusted to meet age-specific glycemic goals throughout course of study.
Study NCT00564018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine
Description: Dosage to be adjusted to meet age-specific glycemic goals throughout course of study.
Study NCT00564018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPH
Description: Dosage to be adjusted to meet age specific glycemic goals throughout course of study.
Study NCT02670941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginger
Description: The ginger oil (GIN-106) was steam distilled from fresh ginger grown in Madagascar. The ginger oil contains 64.23% sesquiterpenes, 18.5% monoterpenes, and 3.28% aldehydes. The aroma of ginger is described as spicy, sweet, and warm.
Study NCT02670941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lavender
Description: The lavender oil (LAV-110) was steam distilled from lavender grown in Kashmir Valley in India. The lavender oil contains 53.22% esters, 31.86% monoterpenols, and 4.88% oxides. The aroma of lavender is described as floral, fresh, herbaceous, and sweet.
Study NCT02670941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orange
Description: The orange oil (ORG-114) was cold-pressed and steam distilled from oranges in South Africa. The orange oil contains 97.21% monoterpenes, 0.73% aldehydes, and 0.7% monoterpenols. The aroma of orange is described as citrus, fresh, fruity, and sweet.
Study NCT02670941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Jojoba
Description: The jojoba oil is certified organic and pesticide-free pure oil. Jojoba has a mild scent and can be used as a fixative for other essential oils.
Study NCT00555490 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy protein
Description: 35 % of protein from soy protein for 4-years
Study NCT02787954 — intervention group
Intervention type: PROCEDURE
Intervention: TACE
Description: Procedure for giving chemotherapy directly to tumor cells.
Study NCT02787954 — intervention group
Intervention type: PROCEDURE
Intervention: Y-90
Description: Using a combination of radiation and chemotherapy directly on the tumor cells to cause cell death.
Study NCT02787954 — intervention group
Intervention type: PROCEDURE
Intervention: MWA
Description: Using heat to kill tumor cells.
Study NCT02787954 — intervention group
Intervention type: PROCEDURE
Intervention: IRE
Description: Using energy to disrupt tumor cell activity, thereby causing cellular death.
Study NCT04134676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioned Media
Description: Conditioned Media represents the complete regenerative milieu of cell-sourced secretome and vesicular elements. The soluble components of the secretome may be separated from the microvesicle fraction by centrifugation, filtration, polymer precipitation-based methodologies, ion exchange chromatography and size-exclusion chromatography. Both of these components may be capable of independently triggering regeneration and repair as well as of mediating the de novo organogenesis of tissue-engineered organs ex vivo.
Study NCT00405470 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Advance Medial Pivot Knee Arthroplasty
Description: medial pivot total knee arthroplasty tibial component vs standard posterior stabilized tibial component with post. Medial pivot provides a constrained medial condyle through shape of polyethylene and reduces amount of bone removal on femoral side that would otherwise be removed to accommodate PS post
Study NCT01699789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Improvement Program
Description: The quality improvement program is an evidence-based toolkit from prior studies (see Names above) that supported team leadership, case and care management, medication management, and Cognitive Behavioral Therapy for Depression. The Case management manual supported depression screening and monitoring/tracking of outcomes; patient education and activation, care coordination, and behavioral activation and problem solving. The toolkit includes education on depression and a community health worker manual.
Study NCT01699789 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality Improvement Program
Description: The quality improvement program is an evidence-based toolkit from prior studies (see Names above) that supported team leadership, case and care management, medication management, and Cognitive Behavioral Therapy for Depression. The Case management manual supported depression screening and monitoring/tracking of outcomes; patient education and activation, care coordination, and behavioral activation and problem solving. The toolkit includes education on depression and a community health worker manual.
Study NCT01699789 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resources for Services Expert Team
Description: The expert team consisted for RS consisted of 3 psychiatrists, a psychologist expert in Cognitive Behavioral Therapy, a nurse care manager, a community engagement specialist, a quality improvement expert, and staff support. They team offered 12 web-based seminars to each community on components of collaborative care as well as site visits to primary care clinics on clinical assessment and medication management.
Study NCT01699789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Engagement and Planning Council
Description: The CEP Council was supported by a workbook developed by the overall CPIC Council that provided principles, approach, agendas, and resources for the multi-sector planning meetings. The CEP Councils met twice a month for 4-6 months to develop their plan and met monthly during implementation of trainings. The study Council supported CEP meetings. Community leaders co-led trainings with study experts to help assure sustainability. Each CEP council had $15K to defray costs of venues, materials, and consultations, while the study provided that for RS.
Study NCT00916825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rehabilitation programme getting better together
Description: Mothers and their children (age 0-16) take part in a 3-week, family-oriented oncological rehabilitation programme which consists of medical, psychological and psychooncological treatments for mothers and children.
Study NCT03541382 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OraQuick® HIV Self-Test
Description: Community leaders, including GVHs, Village Health Committee members, Village Development Committee members, and members of key community groups will participate in a workshop to facilitate planning of a HIVST campaign. Identified community distributors, who are unpaid volunteers from the community, will also receive a training package in HIVST promotion.~Campaigns will be conducted over a short period (approximately seven days) and under a fixed budget. Community distributors will deliver HIVST kits free of charge to community members, and provide information on how to self-test and access the nearest clinic for linkage to confirmatory HTS, treatment and prevention. Distributors will also provide HIV prevention messages around serodiscordancy, treatment as prevention and VMMC.
Study NCT04308525 — intervention group
Intervention type: BEHAVIORAL
Intervention: Early ambulation
Description: Early ambulation will help prevent postoperative infections, especially pneumonia and urinary tract infections. Additionally it will prevent constipation by promotion of bowel-movement and function and prevent thromboembolic complications. Patients undergoing surgery with a free fibula flap are currently unable to ambulate for 6 to 7 days while a split-thickness skin-graft is healing. We will apply a pressure dressing to the wound which makes ambulation possible immediately after surgery (or after return from the ICU). Likewise, all other patient groups will be encouraged to fully ambulate on POD (post-operative day) 1 or POD 2.
Study NCT04308525 — intervention group
Intervention type: BEHAVIORAL
Intervention: Early oral feeding
Description: To monitor the patients' nutritional status, blood samples will be taken to identify risk of refeeding syndrome and patients will be evaluated according to the current guidelines from the ENT (ear-, nose-, throat-) department. We wil use the ESPEN guidelines for nutritional risk screening (NRS-2002), which have been validated for head and neck cancer patients to perform a risk assessment for malnutrition. A consultation with a clinical dietician will be arranged in order to calculate the required daily nutritional intake. Patients in risk of refeeding syndrome will be closely monitored in the outpatient clinic during the time from the MDT(Multi Disciplinary Team) conference to the day of surgery. Patients in need of additional nutritional support will be provided with supplementary energy/protein drinks. Some patients may need closer monitoring, guidance regarding extra meals and to have a nasogastric tube placed to get used to the tube and optimize pre-operative nutritional status.
Study NCT04308525 — intervention group
Intervention type: OTHER
Intervention: Multimodal opioid-sparing analgesia
Description: On-label use of already approved drugs including perioperative dexamethasone, administered with the aim of reducing opioid intake.~Pre-operatively the patients are given 400 mg of Celebra. During surgery 24 mg of dexamethasone is administered. The post-operative regimen consists of 12 mg of Dexamethasone 48 and 96 hours post-operatively, 200 mg of Celebra morning and evening (maximum 14 days) and 1g of paracetamol times four times daily. Morphine will only be administered when assessed necessary with a dose of 10 mg p.n. maximum six times a day.
Study NCT04308525 — intervention group
Intervention type: PROCEDURE
Intervention: Goal-directed fluid therapy
Description: Focus on avoidance of over-hydration. Aim for fluid-load after surgery: max: +1000-1500 ml
Study NCT04308525 — intervention group
Intervention type: PROCEDURE
Intervention: CAD/CAM system for reconstructive plates
Description: Computer-assisted design and modelling (CAD/CAM) are a system for pre-operative planning and construction of reconstructive plates used for mandibular reconstruction. This will help reduce the operating-time, as the maxillofacial surgeon will bring a pre-bent reconstructive plate to the procedure instead of manually forming it during surgery. Already implemented for several procedures in the department.
Study NCT04308525 — intervention group
Intervention type: OTHER
Intervention: Functional discharge criteria
Description: Introduction of a number of functional discharge criteria to avoid prolonged postoperative hospitalisation
Study NCT04308525 — intervention group
Intervention type: OTHER
Intervention: Standard/historical postoperative regimen
Description: Non-formalised historical peri- and postoperative regimen.
Study NCT03397849 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention using mobile technology
Description: Each study patients that are randomized to IMT plus usual care group will receive a group of smart devices including mobile phone (Vestel Venus e2) (Vestel, Manisa, Turkey), wristband (Xiaomi band 2) (Beijing Xiaomi Technology Co., Beijing, China), weight scale (Bluecat, Yongkang Tiansheng Electronic Co., Zhejiang, China) and blood pressure monitor (Clever Chek TD-3250) (TaiDoc Technology Co., Taipei County, Taiwan)
Study NCT02411578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-Pen Mini™ (glucagon injection)
Description: 1st BG check, 1st treatment~1. BG is 50-69 mg/dl, treatment is 150 µg of glucagon~2. BG is 40-49 mg/dl, treatment is 300 µg of glucagon~15 min later, 2nd BG check, 2nd treatment~1. BG is 60-69 mg/dl, no treatment~2. BG is 50-59 mg/dl, treatment is 150 µg of glucagon~3. BG is \<50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~30 minutes later, 3rd BG check, 3rd treatment~1. BG is >=70, no treatment~2. BG is \<70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~(150 µg of glucagon per syringe)
Study NCT02411578 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose Tablets
Description: 1st BG check, 1st treatment~1. BG is 50-69 mg/dl, treatment is 15 grams of carbohydrates~2. BG is 40-49 mg/dl, treatment is 30 grams of carbohydrates~15 min later, 2nd BG check, 2nd treatment~1. BG is 60-69 mg/dl, no treatment~2. BG is 50-59 mg/dl, treatment is 15 grams of carbohydrates~3. BG is \<50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~30 minutes later, 3rd BG check, 3rd treatment~1. BG is >=70, no treatment~2. BG is \<70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~(5 grams of fast-acting carbohydrates (D-Glucose) per tablet)
Study NCT04233593 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide
Description: Endotoxin E Coli
Study NCT02340091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA IDF plus
Study NCT02340091 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA IDF
Study NCT01231516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: 50mg once daily
Study NCT01231516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: 400mg twice daily
Study NCT01231516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1349572 Placebo
Description: Inactive placebo tablet once daily
Study NCT01231516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir Placebo
Description: Inactive placebo tablet twice daily
Study NCT03700749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% chlorhexidine + non-coated suture
Description: Interventions:~2% alcoholic chlorhexidine non-coated suture
Study NCT03700749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% chlorhexidine + coated suture
Description: Interventions:~2% alcoholic chlorhexidine triclosan coated suture
Study NCT03700749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10%povidone-iodine + non-coated suture
Description: Interventions:~10% povidone-iodine non-coated suture non-coated suture
Study NCT03700749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10%povidone-iodine + coated suture
Description: Interventions:~10% povidone-iodine triclosan coated suture